Tesamorelin vs Sermorelin

By GetOPT Review Team · November 02, 2026 ·Part of our Peptide Therapy Guide

The tesamorelin vs sermorelin comparison is primarily about regulatory status. Both are synthetic analogs of growth hormone-releasing hormone (GHRH). Tesamorelin is sold as Egrifta SV, a U.S. Food and Drug Administration (FDA)-approved drug for a specific use. Sermorelin was previously approved as Geref, but those approvals were withdrawn in 2009. Sermorelin offered today is compounded and does not have a current FDA-approved finished-product label.^1,2 That distinction should come before any discussion of expected effects.

The Regulatory Status in Tesamorelin vs Sermorelin

Current regulatory status is the clearest difference between these peptides. Tesamorelin has an active FDA-approved product label. Sermorelin has an approval history, but no FDA-approved sermorelin product is available today.^1,2

Peptide	Regulatory status	Primary approved use	Manufacturer/label
Tesamorelin (Egrifta SV)	FDA-approved finished drug product	Reduction of excess abdominal fat in adults with human immunodeficiency virus (HIV)-associated lipodystrophy	Theratechnologies Inc. / Egrifta SV prescribing information¹
Sermorelin (formerly Geref)	Formerly FDA approved. Both Geref approvals were withdrawn effective June 18, 2009	No current approved use. Geref historically covered growth hormone deficiency-related uses	EMD Serono / former Geref regulatory record²

The table does not establish that one peptide will produce better results for you. It shows that each option enters a prescribing conversation with a different label, evidence record, and regulatory position.

Tesamorelin’s Current FDA Approval

Egrifta SV is approved for reducing excess abdominal fat in HIV-infected adults with lipodystrophy.¹ Lipodystrophy refers to abnormal changes in how body fat is stored or distributed. The Egrifta SV indication applies to that defined population and clinical problem.

The FDA label does not extend the indication to general fat loss, bodybuilding, or anti-aging. A prescription outside the approved indication would require a separate clinical rationale, and the label cannot be used as evidence for those other goals.

Peer-reviewed reviews describe tesamorelin as a synthetic GHRH analogue developed for excess abdominal fat associated with HIV lipodystrophy.^3,4 One review reported reductions in visceral adipose tissue during treatment for up to 52 weeks. It also reported that visceral fat accumulated again after treatment stopped.³

Those findings support the approved indication. They do not establish how tesamorelin compares with sermorelin because the reviews did not test the two peptides against each other.

Sermorelin’s Approval and Withdrawal Record

Sermorelin was once sold as the FDA-approved drug Geref. The ampule formulation was approved under New Drug Application (NDA) 19-863 on December 28, 1990. The vial formulation was approved under NDA 20-443 on September 26, 1997.²

EMD Serono asked the FDA to withdraw both approvals in December 2008. The FDA withdrew the approvals effective June 18, 2009.²

The reason for that withdrawal needs to be stated accurately. In 2013, the FDA reviewed its files and determined that Geref had not been withdrawn for reasons of safety or effectiveness.² The record describes a manufacturer-requested discontinuation. It was not an FDA safety action.

That history does not create a current approval. If your physician discusses sermorelin today, the product would come through compounding rather than through an active Geref label.

The FDA record also does not compare current compounded sermorelin with the former Geref product. It does not establish that the preparations are equivalent, and it does not establish that they differ in quality or clinical effect.² Your prescriber must evaluate the specific compounded preparation being considered.

Weight-Loss Claims in Tesamorelin vs Sermorelin

Egrifta SV is not approved for weight-loss management. Its prescribing information states that the drug has a weight-neutral effect.¹ That limitation sits alongside the approved indication for reducing excess abdominal fat in adults with HIV lipodystrophy.

Reducing visceral adipose tissue in a defined medical condition is different from an approval for general weight loss. A change in abdominal fat distribution also does not automatically mean a lower number on the scale.

The available sermorelin record does not support a weight-loss ranking either. It provides the history of Geref’s approvals and withdrawal, without a current FDA-approved indication for weight management.²

If your goal is general weight loss, this comparison does not identify a preferred peptide. Your physician should first assess the factors behind your weight concern, including metabolic health, hormone patterns, sleep, medication history, and nutrition. That evaluation gives the peptide discussion a clinical purpose.

Shared GHRH Mechanism and Different Evidence Records

Tesamorelin and sermorelin belong to the GHRH analogue class. GHRH is a hormone signal involved in growth hormone release, and an analogue is a synthetic compound designed to resemble that signal.⁴

A shared mechanism does not create a shared indication. It also does not show that the two peptides produce the same effect in the same population. The Egrifta SV label applies to tesamorelin and its approved use alone.¹

Tesamorelin has peer-reviewed clinical-trial literature supporting its approved indication. Reviews describe reductions in visceral adipose tissue among people with HIV-associated lipodystrophy, while also documenting the return of visceral fat after discontinuation.^3,4

The evidence supplied for currently compounded sermorelin does not include an equivalent peer-reviewed efficacy trial. That absence does not prove that sermorelin has no evidence from earlier development or clinical use. It means the available record cannot support a direct efficacy comparison with tesamorelin.

The FDA label and cited reviews include no head-to-head trial comparing tesamorelin with sermorelin. Claims that one is stronger or works better would go beyond the evidence used for this comparison.

Branded and Compounded Product Paths

An FDA-approved finished drug has a specific prescribing label. That label identifies the approved indication, limitations of use, manufacturer, and regulatory record.

A compounded preparation is made by a pharmacy from a prescription formula. It does not carry its own FDA-approved finished-product label. Sermorelin offered today follows this route because the Geref approvals are no longer active.²

This difference changes the basis for your conversation with a prescriber. Egrifta SV can be discussed against an active label for one defined indication. Compounded sermorelin requires your physician to explain why that preparation fits your goal and how its current evidence applies to you.

Regulatory status alone cannot predict your response. It does tell you which claims are supported by an approved label and where your physician must work from a compounded-treatment rationale.

A Prescriber’s Decision Framework

Your treatment goal determines whether either peptide belongs in the discussion. If you are being evaluated for excess abdominal fat associated with HIV lipodystrophy, Egrifta SV has the relevant FDA-approved indication.¹

If your goal is general weight loss, the Egrifta SV label expressly excludes that use. The evidence here also does not support choosing compounded sermorelin as the better weight-loss option.

This comparison is not a tool for selecting a peptide on your own. Your health history, current medications, symptoms, laboratory pattern, and reason for considering treatment all affect a prescriber’s decision.

A head-to-head clinical trial could change the efficacy comparison. A newly approved sermorelin product with a current label could also change the regulatory comparison. Until either exists, your prescriber has to separate the documented indication from goals that fall outside it.

The tesamorelin peptide guide explains tesamorelin’s mechanism and clinical evidence in more detail. It is the better next page if you want to understand tesamorelin outside this head-to-head comparison.

The tesamorelin and ipamorelin page addresses that specific combination. The sermorelin vs ipamorelin comparison and sermorelin vs CJC-1295 comparison cover those separate pairings without mixing their evidence into this decision.

The Opt Take on Tesamorelin and Sermorelin

We start with an initial panel of 55+ biomarkers, followed by a 1:1 physician review. If a GHRH analogue enters the discussion, our physician reads that option against your broader hormone and metabolic pattern, symptoms, goals, and current medications.

We do not use a standard peptide plan. The peptide name alone cannot show whether the option fits the reason you are seeking care.

Your labs and physician consultation repeat every 3 to 4 months. The next panel gives us new data on whether the plan should continue or change. At each retest, we revisit the tesamorelin vs sermorelin decision against what your labs and symptoms did.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

Is tesamorelin FDA approved?

Yes. Tesamorelin is FDA approved as Egrifta SV for reducing excess abdominal fat in HIV-infected adult patients with lipodystrophy.¹ The approval does not cover general weight-loss management, and the label describes Egrifta SV as weight neutral.

Is sermorelin still available?

Yes, sermorelin is available through compounding. It is not currently available as an FDA-approved finished drug product. The former FDA-approved product, Geref, had its approvals withdrawn effective June 18, 2009, after the manufacturer requested withdrawal.²

Which is better, tesamorelin or sermorelin?

Neither peptide can be named better from the evidence used here. No head-to-head trial in the cited record compares tesamorelin with sermorelin. The supported differences are regulatory status, approved use, and evidence maturity. Your prescriber should compare those facts with your goal and health profile.

What is the difference between tesamorelin and sermorelin?

Both are synthetic GHRH analogues, but they have different regulatory positions. Tesamorelin is currently FDA approved as Egrifta SV for a specific indication. Sermorelin was formerly approved as Geref and is now offered through compounding without a current FDA-approved finished-product label.^1,2

Is sermorelin FDA approved?

No. Sermorelin is not an FDA-approved product today. Its former approvals under the Geref name were withdrawn in 2009 at the manufacturer’s request. The FDA later determined that the products were not withdrawn for reasons of safety or effectiveness.²